Search research articles
Contact Us
Filters
Showing results (1-10 of 73) with videos related to
Page
of 8
Sort By:
Therapeutic Advances in Psychopharmacology
|
April 3, 2018
The antipsychotic landscape: dopamine and beyond
Paul D Morrison, Robin M Murray
Expert Review of Neurotherapeutics
|
December 26, 2006
Schizophrenia: more evidence for less glutamate
Paul D Morrison, Lyn S Pilowsky
Current Biology : CB
|
December 20, 2005
Schizophrenia
Paul D Morrison, Robin M Murray
Dialogues in Clinical Neuroscience
|
November 9, 2020
Cannabis points to the synaptic pathology of mental disorders: how aberrant synaptic components disrupt the highest psychological functions
Paul D Morrison, Robin M Murray
Schizophrenia Bulletin
|
June 3, 2009
From real-world events to psychosis: the emerging neuropharmacology of delusions
Paul D Morrison, R M Murray
Journal of Psychopharmacology (Oxford, England)
|
February 13, 2025
The mechanism of action of clozapine
Paul D Morrison, Sameer Jauhar, Allan H Young
Current Pharmaceutical Design
|
June 22, 2012
Cannabis in the arm: what can we learn from intravenous cannabinoid studies?
Amir Englund, James M Stone, Paul D Morrison
The British Journal of Psychiatry : the Journal of Mental Science
|
March 2, 2002
Fear knot. Neurobiological disruption of long-term fear memory
Paul D Morrison, Judith Allardyce, Joseph P McKane
BMC Complementary and Alternative Medicine
|
December 17, 2014
Analysis of the volatile organic compounds from leaves, flower spikes, and nectar of Australian grown Agastache rugosa
Hanaa Yamani, Nitin Mantri, Paul D Morrison, et al.
Journal of Psychopharmacology (Oxford, England)
|
January 30, 2007
Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review
James M Stone, Paul D Morrison, Lyn S Pilowsky
Page
of 8
Search research articles
Search
Showing results (1-10 of 73) with videos related to
Sort By:
Page
of 8
Therapeutic Advances in Psychopharmacology
|
April 3, 2018
The antipsychotic landscape: dopamine and beyond
Paul D Morrison, Robin M Murray
Expert Review of Neurotherapeutics
|
December 26, 2006
Schizophrenia: more evidence for less glutamate
Paul D Morrison, Lyn S Pilowsky
Current Biology : CB
|
December 20, 2005
Schizophrenia
Paul D Morrison, Robin M Murray
Dialogues in Clinical Neuroscience
|
November 9, 2020
Cannabis points to the synaptic pathology of mental disorders: how aberrant synaptic components disrupt the highest psychological functions
Paul D Morrison, Robin M Murray
Schizophrenia Bulletin
|
June 3, 2009
From real-world events to psychosis: the emerging neuropharmacology of delusions
Paul D Morrison, R M Murray
Journal of Psychopharmacology (Oxford, England)
|
February 13, 2025
The mechanism of action of clozapine
Paul D Morrison, Sameer Jauhar, Allan H Young
Current Pharmaceutical Design
|
June 22, 2012
Cannabis in the arm: what can we learn from intravenous cannabinoid studies?
Amir Englund, James M Stone, Paul D Morrison
The British Journal of Psychiatry : the Journal of Mental Science
|
March 2, 2002
Fear knot. Neurobiological disruption of long-term fear memory
Paul D Morrison, Judith Allardyce, Joseph P McKane
BMC Complementary and Alternative Medicine
|
December 17, 2014
Analysis of the volatile organic compounds from leaves, flower spikes, and nectar of Australian grown Agastache rugosa
Hanaa Yamani, Nitin Mantri, Paul D Morrison, et al.
Journal of Psychopharmacology (Oxford, England)
|
January 30, 2007
Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review
James M Stone, Paul D Morrison, Lyn S Pilowsky
Page
of 8